Researchers delivered an mRNA‑based epigenetic editor (Epi‑Reg) to nonhuman primates’ livers and achieved durable suppression of PCSK9 with sustained LDL cholesterol reductions for nearly a year, according to a Nature Biotechnology report. The approach uses transient mRNA to install reversible epigenetic changes rather than permanent DNA edits. Authors reported efficacy in human cells, mice and primates, arguing the method balances durability with a potentially improved safety profile versus nuclease‑based genome editing. The study highlighted reversibility and safety markers across animal studies, though long‑term human safety and regulatory pathways remain to be defined. If translated to humans, an epigenetic editing platform could offer a single‑administration, long‑duration alternative to chronic LDL‑lowering therapies and provide a new modality for cardiometabolic risk reduction.